Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Active not recruiting 5Unknown 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Prostate Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 36Androgen Antagonists 35Radiosurgery 33Radiotherapy 31darolutamide 26Prednisone 26Abiraterone Acetate 25Leuprolide 22Docetaxel 22apalutamide 21abiraterone 19Pluvicto 19Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12X-Rays 11Surveys and Questionnaires 11pembrolizumab 10luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × Radium-223 × Clear all
NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT06389097 2026-03-30

(SEEtoTREAT)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Recruiting
80 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡